Research status of kidney protection by proline hydroxylase inhibitors
10.13699/j.cnki.1001-6821.2024.02.029
- VernacularTitle:脯氨酰羟化酶抑制药对肾保护作用的研究现状
- Author:
Yue-Hua HU
1
;
Miao SU
;
Qiang CHEN
Author Information
1. 内蒙古科技大学包头医学院第一临床医学院,内蒙古自治区包头 014010;内蒙古科技大学包头医学院第一附属医院心内科,内蒙古自治区包头 014010
- Keywords:
prolyl hydroxylase inhibitor;
hypoxia inducible factor;
kidney protection;
mechanism of action
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(2):289-293
- CountryChina
- Language:Chinese
-
Abstract:
Targeted regulation of hypoxia inducible factor(HIF)pathway can provide therapeutic basis for inflammatory anemia,hypoxic nephropathy,cardiovascular diseases related to chronic kidney disease and other hypoxic diseases.At present,the first drug to act on the HIF pathway,roxadustat,has been used for the treatment of renal anemia,and other prolyl hydroxylase(PHD)inhibitors are also in clinical research.This article mainly reviews the various pathways and mechanisms of the protective effect of PHD inhibitors on the kidneys.
